pSivida Reports Presentation Of Additional Positive 24-Month Data From Iluvien(R) Phase 3 FAME™ Study For Diabetic Macular Edema At Angiogenesis
pSivida Corp…
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.